3B Blackbio Diagnostics Ltd

3BBLACKBIOHealthcare Service Provider
1627.55+0.00 (+0.00%)
As on 08 Feb 2026, 11:51 amMarket Closed

Fundamental Score

...

3B Blackbio Diagnostics Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Good

Return on Equity

19.40%
Excellent

Return on Capital Employed

25.75%
Excellent

Operating Profit Margin (5Y)

55.44%
Poor

Dividend Yield

0.32%

Valuation Metrics

Excellent

Price to Earnings

22.01x

Market Capitalization

1.08K (Cr)

Industry P/E

39.28x

Growth Metrics

Poor

YoY Quarterly Profit Growth

0.41%
Average

YoY Quarterly Sales Growth

16.30%
Excellent

Sales Growth (5Y)

27.29%
Excellent

EPS Growth (5Y)

40.23%
Excellent

Profit Growth (5Y)

44.03%

Financial Health

Excellent

Debt to Equity

0.00x
Excellent

Interest Coverage

599.27x
Excellent

Free Cash Flow (5Y)

218.07 (Cr)

Ownership Structure

Average

Promoter Holding

41.28%
Poor

FII Holding

2.64%
Poor

DII Holding

1.82%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
41.28%
Promoter Holding
1.08K (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of 3BBLACKBIO across key market metrics for learning purposes.

Positive Indicators

12 factors identified

Strong Return on Equity (19.40%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (25.75%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Operating Margins (55.44%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Attractive Valuation (P/E: 22.01 vs Industry: 39.28)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.

Strong Revenue Growth (16.30%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (27.29% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Excellent EPS Growth (40.23% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (44.03% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (599.27x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Strong Cash Generation (₹218.07 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 4.46%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

Financial Statements

Comprehensive financial data for 3B Blackbio Diagnostics Ltd

About 3BBLACKBIO

Business Overview

3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and training services. 3B Blackbio Dx Limited was incorporated in 1972 and is headquartered in Bhopal, India.

Company Details

Symbol:3BBLACKBIO
Industry:Healthcare Service Provider
Sector:Healthcare Service Provider

Key Leadership

Mr. Dhirendra Kuber Dubey
Chairman & MD
Mr. Nikhil Kuber Dubey
CFO & Whole-Time Director
Ms. Navneet Kaur
Compliance Officer & Company Secretary

3BBLACKBIO Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)19.40%
Return on Capital Employed25.75%
Operating Profit Margin (5Y)55.44%
Debt to Equity Ratio0.00
Interest Coverage Ratio599.27

Growth & Valuation

Sales Growth (5Y)27.29%
Profit Growth (5Y)44.03%
EPS Growth (5Y)40.23%
YoY Quarterly Profit Growth0.41%
YoY Quarterly Sales Growth16.30%

Frequently Asked Questions

What is the current price of 3B Blackbio Diagnostics Ltd (3BBLACKBIO)?

As of 08 Feb 2026, 11:51 am IST, 3B Blackbio Diagnostics Ltd (3BBLACKBIO) is currently trading at ₹1627.55. The stock has a market capitalization of ₹1.08K (Cr).

Is 3BBLACKBIO share price Overvalued or Undervalued?

3BBLACKBIO is currently trading at a P/E ratio of 22.01x, compared to the industry average of 39.28x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.

What factors affect the 3B Blackbio Diagnostics Ltd share price?

Key factors influencing 3BBLACKBIO's price include its quarterly earnings growth (Sales Growth: 16.30%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is 3B Blackbio Diagnostics Ltd a good stock for long-term investment?

3B Blackbio Diagnostics Ltd shows a 5-year Profit Growth of 44.03% and an ROE of 19.40%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.

How does 3B Blackbio Diagnostics Ltd compare with its industry peers?

3B Blackbio Diagnostics Ltd competes with major peers in the Healthcare Service Provider. Investors should compare 3BBLACKBIO's P/E of 22.01x and ROE of 19.40% against the industry averages to determine its competitive standing.

What is the P/E ratio of 3BBLACKBIO and what does it mean?

3BBLACKBIO has a P/E ratio of 22.01x compared to the industry average of 39.28x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹22 for every ₹1 of annual earnings.

How is 3BBLACKBIO performing according to Bull Run's analysis?

3BBLACKBIO has a Bull Run fundamental score of 66.1/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does 3BBLACKBIO belong to?

3BBLACKBIO operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting 3B Blackbio Diagnostics Ltd.

What is Return on Equity (ROE) and why is it important for 3BBLACKBIO?

3BBLACKBIO has an ROE of 19.40%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently 3B Blackbio Diagnostics Ltd generates profits from shareholders' equity.

How is 3BBLACKBIO's debt-to-equity ratio and what does it indicate?

3BBLACKBIO has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is 3BBLACKBIO's dividend yield and is it a good dividend stock?

3BBLACKBIO offers a dividend yield of 0.32%, which means you receive ₹0.32 annual dividend for every ₹100 invested.

How has 3BBLACKBIO grown over the past 5 years?

3BBLACKBIO has achieved 5-year growth rates of: Sales Growth 27.29%, Profit Growth 44.03%, and EPS Growth 40.23%.

What is the promoter holding in 3BBLACKBIO and why does it matter?

Promoters hold 41.28% of 3BBLACKBIO shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is 3BBLACKBIO's market capitalization category?

3BBLACKBIO has a market capitalization of ₹1081 crores, placing it in the Small-cap category.

How volatile is 3BBLACKBIO stock?

3BBLACKBIO has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for 3BBLACKBIO?

3BBLACKBIO has a 52-week high of ₹N/A and low of ₹N/A.

What is 3BBLACKBIO's operating profit margin trend?

3BBLACKBIO has a 5-year average Operating Profit Margin (OPM) of 55.44%, indicating the company's operational efficiency.

How is 3BBLACKBIO's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 16.30% and YoY Profit Growth of 0.41%.

What is the institutional holding pattern in 3BBLACKBIO?

3BBLACKBIO has FII holding of 2.64% and DII holding of 1.82%. Significant institutional holding often suggests professional confidence in the stock.